Document:

<PAGE>

                                                                  EXHIBIT 10.14

                            INDEMNIFICATION AGREEMENT

            This Indemnification Agreement is made this ____ day of ___________,
200__, between Micrus Corporation, a Delaware corporation (the "Company"), and
____________ (the "Indemnitee").

                              W I T N E S S E T H:

            WHEREAS, the Indemnitee is a director and/or officer of the Company.

            WHEREAS, highly competent persons have become more reluctant to
serve publicly-held corporations as directors or in other capacities unless they
are provided with adequate protection through insurance or adequate
indemnification against inordinate risks of claims and actions against them
arising out of their service to and activities on behalf of the corporation.

            WHEREAS, in recognition of Indemnitee's need for substantial
protection against personal liability in order to enhance Indemnitee's continued
service to the Company in an effective manner and Indemnitee's reliance on the
provisions of the Company's Certificate of Incorporation ("Certificate of
Incorporation") and the Company's Bylaws (the "Bylaws") requiring
indemnification of the Indemnitee to the fullest extent permitted by law, and in
part to provide Indemnitee with specific contractual assurance that the
protection promised by such Certificate of Incorporation and Bylaws will be
available to Indemnitee (regardless of, among other things, any amendment to or
revocation of such Certificate of Incorporation or Bylaws or any change in the
composition of the Company's Board of Directors or acquisition transaction
relating to the Company), the Company wishes to provide in this Agreement for
the indemnification of and the advancing of expenses to Indemnitee to the
fullest extent (whether partial or complete) permitted by law and as set forth
in this Agreement.

            WHEREAS, the Certificate of Incorporation, the Bylaws and the
General Corporation Law of the State of Delaware ("DGCL") expressly provide that
the indemnification provisions set forth therein are not exclusive and thereby
contemplate that contracts may be entered into between the Company and members
of the board of directors, officers and other persons with respect to
indemnification.

            WHEREAS, it is reasonable, prudent and necessary for the Company
contractually to obligate itself to indemnify, and to advance expenses on behalf
of, such persons to the fullest extent permitted by applicable law so that they
will serve or continue to serve the Company free from undue concern that they
will not be so indemnified.

            WHEREAS, this Agreement is a supplement to and in furtherance of the
Certificate of Incorporation and Bylaws and any resolutions adopted pursuant
thereto and shall not be deemed a substitute therefor, nor to diminish or
abrogate any rights of Indemnitee thereunder.

<PAGE>

            NOW, THEREFORE, in consideration of the premises and of Indemnitee
agreeing to serve or continuing to serve the Company directly or, at its
request, with another enterprise, and intending to be legally bound hereby, the
parties hereto agree as follows:

            Section 1. Basic Indemnification Agreement. (a) In the event
Indemnitee was, is or becomes a party to or witness or other participant in, or
is threatened to be made a party to or witness or other participant in, a Claim
(as defined in Section 9(b) herein) by reason of (or arising in part out of) an
Indemnifiable Event (as defined in Section 9(d) herein), the Company shall
indemnify Indemnitee to the fullest extent permitted by law as soon as
practicable but in any event no later than 30 days after written demand is
presented to the Company, against any and all Expenses (as defined in Section
9(c) herein), judgments, fines, penalties and amounts paid in settlement
(including all interest, assessments and other charges paid or payable in
connection therewith) of such Claim actually and reasonably incurred by or on
behalf of Indemnitee in connection with such Claim and any federal, state, local
or foreign taxes imposed on Indemnitee as a result of the actual or deemed
receipt of any payments under this Agreement. If requested by Indemnitee in
writing, the Company shall advance (within ten business days of such written
request) any and all Expenses to Indemnitee (an "Expense Advance").
Notwithstanding anything in this Agreement to the contrary, and except as
provided in Section 3, prior to a Change of Control (as defined in Section 9
herein) and except as set forth in Sections 1(b) and 7, Indemnitee shall not be
entitled to indemnification pursuant to this Agreement in connection with any
Claim (i) initiated by Indemnitee against the Company or any director or officer
of the Company unless the Company has joined in or consented to the initiation
of such Claim; (ii) made on account of Indemnitee's conduct which constitutes a
breach of Indemnitee's duty of loyalty to the Company or its stockholders or is
an act or omission not in good faith or which involves intentional misconduct or
a knowing violation of the law; or (iii) arising from the purchase and sale by
Indemnitee of securities in violation of Section 16(b) of the Securities
Exchange Act of 1934, as amended.

            (b)   Notwithstanding the foregoing, (i) the indemnification
obligations of the Company under Section 1(a) shall be subject to the condition
that the Reviewing Party shall not have determined (in a written opinion, in any
case in which the special independent counsel referred to in Section 2 hereof is
involved) that Indemnitee would not be permitted to be indemnified under
applicable law, and (ii) the obligation of the Company to make an Expense
Advance pursuant to Section 1(a) shall be subject to the condition that the
Company receives an undertaking that, if, when and to the extent that the
Reviewing Party determines that Indemnitee would not be permitted to be so
indemnified under applicable law, the Company shall be entitled to be reimbursed
by Indemnitee (who hereby agrees to reimburse the Company) for all such amounts
theretofore paid; provided, however, that if Indemnitee has commenced legal
proceedings in the Court of Chancery of the State of Delaware (the "Delaware
Court") to secure a determination that Indemnitee should be indemnified under
applicable law, any determination made by the Reviewing Party that Indemnitee
would not be permitted to be indemnified under applicable law shall not be
binding and Indemnitee shall not be required to reimburse the Company for any
Expense Advance until a final judicial determination is made with respect
thereto (as to which all rights of appeal therefrom have been exhausted or
lapsed). Indemnitee's obligation to reimburse the Company for Expense Advances
shall be unsecured and no interest

                                        2

<PAGE>

shall be charged thereon. If there has not been a Change in Control, the
Reviewing Party shall be selected by the Board of Directors, and if there has
been such a Change in Control, the Reviewing Party shall be the special
independent counsel referred to in Section 2 hereof. If there has been no
determination by the Reviewing Party or if the Reviewing Party determines that
Indemnitee substantively would not be permitted to be indemnified in whole or in
part under applicable law, Indemnitee shall have the right to commence
litigation in the Delaware Court seeking an initial determination by the court
or challenging any such determination by the Reviewing Party or any aspect
thereof and the Company hereby consents to service of process and to appear in
any such proceeding. Any determination by the Reviewing Party otherwise shall be
conclusive and binding on the Company and Indemnitee. The Company shall
indemnify Indemnitee for Expenses incurred by Indemnitee in connection with the
successful establishment or enforcement, in whole or in part, by Indemnitee of
Indemnitee's right to indemnification or advances.

            Section 2. Change in Control. The Company agrees that if there is a
Change in Control of the Company (other than a Change in Control which has been
approved by two- thirds or more of the Company's Board of Directors who were
directors immediately prior to such Change in Control) then with respect to all
matters thereafter arising concerning the rights of Indemnitee to indemnity
payments and Expense Advances under this Agreement or any other agreement, the
Bylaws or Certificate of Incorporation now or hereafter in effect relating to
Claims for Indemnifiable Events, the Company shall seek legal advice only from
special independent counsel selected by Indemnitee and approved by the Company
(which approval shall not be unreasonably withheld or delayed) and who has not
otherwise performed services for the Company within the last five years (other
than in connection with such matters) or for Indemnitee. In the event that
Indemnitee and the Company are unable to agree on the selection of the special
independent counsel, such special independent counsel shall be selected by lot
from among at least five law firms with offices in the State of Delaware having
more than fifty attorneys, having a rating of "av" or better in the then current
Martindale Hubbell Law Directory and having attorneys which specialize in
corporate law. Such selection shall be made in the presence of Indemnitee (and
his legal counsel or either of them, as Indemnitee may elect). Such counsel,
among other things, shall, within 90 days of its retention, render its written
opinion to the Company and Indemnitee as to whether and to what extent
Indemnitee would be permitted to be indemnified under applicable law. The
Company agrees to pay the reasonable fees of the special independent counsel
referred to above and to fully indemnify such counsel against any and all
expenses (including attorneys' fees), claims, liabilities, and damages arising
out of or relating to this Agreement or its engagement pursuant hereto.

            Section 3. Indemnification for Additional Expenses. The Company
shall indemnify Indemnitee against any and all expenses (including attorneys'
fees) and, if requested by Indemnitee in writing, shall (within ten business
days of such written request) advance such expenses to Indemnitee, which are
incurred by Indemnitee in connection with any Claim asserted against or action
brought by Indemnitee for (i) indemnification or advance payment of Expenses by
the Company under this Agreement or any other agreement, the Bylaws or
Certificate of Incorporation now or hereafter in effect relating to Claims for
Indemnifiable Events and/or (ii) recovery under any directors' and officers'
liability insurance policies maintained by the

                                        3

<PAGE>

Company, regardless of whether Indemnitee ultimately is determined to be
entitled to such indemnification, advance expense payment or insurance recovery,
as the case may be. The Indemnitee shall qualify for advances solely upon the
execution and delivery to the Company of an undertaking providing that the
Indemnitee undertakes to repay the advance to the extent that it is ultimately
determined that the Indemnitee is not entitled to be indemnified by the Company.

            Section 4. Partial Indemnity, Etc. If Indemnitee is entitled under
any provisions of this Agreement to indemnification by the Company of some or a
portion of the Expenses, liabilities, judgments, fines, penalties and amounts
paid in settlement of a Claim but not, however, for all of the total amount
thereof, the Company shall nevertheless indemnify Indemnitee for the portion
thereof to which Indemnitee is entitled. Moreover, notwithstanding any other
provision of this Agreement, to the extent that Indemnitee has been successful
on the merits or otherwise in defense of any or all Claims relating in whole or
in part to an Indemnifiable Event or in defense of any issue or matter therein,
including dismissal without prejudice, Indemnitee shall be indemnified against
all Expenses incurred in connection therewith. In connection with any
determination by the Reviewing Party or otherwise as to whether Indemnitee is
entitled to be indemnified hereunder the burden of proof shall be on the Company
to establish that Indemnitee is not so entitled.

            Section 5. No Presumption. For purposes of this Agreement, the
termination of any action, suit or proceeding by judgment, order, settlement
(whether with or without court approval) or conviction, or upon a plea of nolo
contendere, or its equivalent, shall not create a presumption that Indemnitee
did not meet any particular standard of conduct or have any particular belief.

            Section 6. Notification and Defense of Claim. Within 30 days after
receipt by Indemnitee of notice of the commencement of a Claim which may involve
an Indemnifiable Event, Indemnitee will, if a claim in respect thereof is to be
made against the Company under this Agreement, submit to the Company a written
notice identifying the proceeding, but the omission so to notify the Company
will not relieve it from any liability which it may have to Indemnitee under
this Agreement unless the Company is materially prejudiced by such lack of
notice. With respect to any such Claim as to which Indemnitee notifies the
Company of the commencement thereof:

            (a)   the Company will be entitled to participate therein at its own
expense;

            (b)   except as otherwise provided below, to the extent that it may
wish, the Company jointly with any other indemnifying party similarly notified
will be entitled to assume the defense thereof, with counsel satisfactory to
Indemnitee. After notice from the Company to Indemnitee of its election to
assume the defense thereof, the Company will not be liable to Indemnitee under
this Agreement for any legal or other expenses subsequently incurred by
Indemnitee in connection with the defense thereof other than reasonable costs of
investigation or as otherwise provided below. Indemnitee shall have the right to
employ its own counsel in such action, suit or proceeding, but the fees and
expenses of such counsel incurred after notice from the Company of its
assumption of the defense thereof shall be at the expense of Indemnitee

                                        4

<PAGE>

unless (i) the employment of counsel by Indemnitee has been authorized by the
Company, (ii) Indemnitee shall have reasonably concluded that there may be a
conflict of interest between the Company and the Indemnitee in the conduct of
the defense of such action, or (iii) the Company shall not in fact have employed
counsel to assume the defense of such action, in each of which cases the fees
and expenses of counsel shall be at the expense of the Company. The Company
shall not be entitled to assume the defense of any claim brought by or on behalf
of the Company or as to which Indemnitee shall have made the conclusion provided
for in clause (ii) above; and

            (c)   the Company shall not be liable to indemnify Indemnitee under
this Agreement for any amounts paid in settlement of any action or claim
effected without its written consent. The Company shall not settle any action or
claim in any manner which would impose any penalty or limitation on Indemnitee
without Indemnitee's written consent. Neither the Company nor Indemnitee will
unreasonably withhold or delay their consent to any proposed settlement.

            Section 7. Non-exclusivity, Etc. The rights of Indemnitee hereunder
shall be in addition to any other rights Indemnitee may have under the
Certificate of Incorporation, the Bylaws, the DGCL, any agreement, a vote of the
stockholders, a resolution of directors or otherwise. No amendment, alteration
or repeal of this Agreement or of any provision hereof shall limit or restrict
any right of Indemnitee under this Agreement in respect of any action taken or
omitted by such Indemnitee acting on behalf of the Company and at the request of
the Company prior to such amendment, alteration or repeal. To the extent that a
change in the DGCL (whether by statute or judicial decision), the Certificate of
Incorporation or the Bylaws permits greater indemnification by agreement than
would be afforded currently under the Certificate of Incorporation, the Bylaws
and this Agreement, it is the intent of the parties hereto that Indemnitee shall
enjoy by this Agreement the greater benefits so afforded by such change. No
right or remedy herein conferred is intended to be exclusive of any other right
or remedy, and every other right and remedy shall be cumulative and in addition
to every other right and remedy given hereunder or now or hereafter existing at
law or in equity or otherwise. The assertion or employment of any right or
remedy hereunder, or otherwise, shall not prevent the concurrent assertion or
employment of any other right or remedy.

            Section 8. Liability Insurance. To the extent the Company maintains
an insurance policy or policies providing directors' and officers' liability
insurance, Indemnitee shall be covered by such policy or policies in accordance
with its or their terms to the maximum extent of the coverage available for any
Company director or officer. If, at the time the Company receives notice from
any source of a Claim as to which Indemnitee is a party or a participant (as a
witness or otherwise), the Company has director and officer liability insurance
in effect, the Company shall give prompt notice of such Proceeding to the
insurers in accordance with the procedures set forth in the respective policies.
The Company shall thereafter take all necessary or desirable action to cause
such insurers to pay, on behalf of the Indemnitee, all amounts payable as a
result of such Claim in accordance with the terms of such policies. In the event
of a Potential Change in Control (as defined in Section 9 herein), the Company
shall maintain in force any and all insurance policies then maintained by the
Company providing directors' and officers' liability insurance, in respect of
Indemnitee, for a period of six years thereafter. The Company

                                        5

<PAGE>

shall indemnify Indemnitee for Expenses incurred by Indemnitee in connection
with any successful action brought by Indemnitee for recovery under any
insurance policy referred to in this Section 8 and shall advance to Indemnitee
the Expenses of such action in the manner provided in Section 3 above.

            Section 9. Certain Definitions.

            (a)   Change in Control: shall be deemed to have occurred if:

                  (i)   before the Company has a class of securities registered
under Section 12 of the Securities Exchange Act of 1934 (the "Exchange Act"):

                        (A)   the Company, or any material subsidiary of the
                  Company, is merged, consolidated or reorganized into or with
                  another corporation or other legal person (an "Acquiring
                  Person") or securities of the Company are exchanged for
                  securities of an Acquiring Person, and as a result of such
                  merger, consolidation, reorganization or exchange less than a
                  majority of the combined voting power of the then outstanding
                  securities of the Acquiring Person immediately after such
                  transaction are held, directly or indirectly, in the aggregate
                  by the holders of Voting Securities immediately prior to such
                  transaction;

                        (B)   the Company, or any material subsidiary of the
                  Company, in any transaction or series of related transactions,
                  sells or otherwise transfers all or substantially all of its
                  assets to an Acquiring Person, and less than a majority of the
                  combined voting power of the then outstanding securities of
                  the Acquiring Person immediately after such sale or transfer
                  are held, directly or indirectly, in the aggregate by the
                  holders of Voting Securities immediately prior to such sale or
                  transfer;

                        (C)   during any period of two consecutive years,
                  individuals who at the beginning of any such period constitute
                  the directors of the Company cease for any reason to
                  constitute at least a majority thereof, unless the election,
                  or the nomination for election by the Company's stockholders,
                  of each director of the Company first elected during such
                  period was approved by a unanimous vote of the directors of
                  the Company then still in office who were directors of the
                  Company at the beginning of any such period;

                        (D)   the Company and its subsidiaries, in any
                  transaction or series of related transactions, sells or
                  otherwise transfers business operations that generated two
                  thirds or more of the

                                        6

<PAGE>

                  consolidated revenues (determined on the basis of the
                  Company's four most recently completed fiscal quarters) of the
                  Company and its subsidiaries immediately prior thereto; or

                        (E)   any other transaction or series of related
                  transactions occur that have substantially the effect of the
                  transactions specified in any of the preceding clauses in this
                  paragraph (i); or

                  (ii)  after the Company has a class of securities registered
under Section 12 of the Exchange Act:

                        (A)   any person, as that term is used in Section 13(d)
                  and Section 14(d)(2) of the Exchange Act, becomes, is
                  discovered to be, or files a report on Schedule 13D or 14D-1
                  (or any successor schedule, form or report) disclosing that
                  such person is a beneficial owner (as defined in Rule 13d-3
                  under the Exchange Act or any successor rule or regulation),
                  directly or indirectly, of securities of the Company
                  representing 20% or more of the total voting power of the
                  Company's then outstanding Voting Securities (unless such
                  person becomes such a beneficial owner in connection with the
                  initial public offering of the Company);

                        (B)   individuals who, as of the consummation date of
                  the Company's initial public offering, constitute the Board of
                  Directors of the Company cease for any reason to constitute at
                  least a majority of the Board of Directors of the Company,
                  unless any such change is approved by a unanimous vote of the
                  members of the Board of Directors of the Company in office
                  immediately prior to such cessation;

                        (C)   the Company, or any material subsidiary of the
                  Company, is merged, consolidated or reorganized into or with
                  an Acquiring Person or securities of the Company are exchanged
                  for securities of an Acquiring Person, and immediately after
                  such merger, consolidation, reorganization or exchange less
                  than a majority of the combined voting power of the then
                  outstanding securities of the Acquiring Person immediately
                  after such transaction are held, directly or indirectly, in
                  the aggregate by the holders of Voting Securities immediately
                  prior to such transaction;

                        (D)   the Company, or any material subsidiary of the
                  Company, in any transaction or series of related transactions,
                  sells or otherwise transfers all or substantially all of its
                  assets to an Acquiring Person, and less than a majority of the
                  combined voting power of the then outstanding securities of
                  the Acquiring Person

                                        7

<PAGE>

                  immediately after such sale or transfer is held, directly or
                  indirectly, in the aggregate by the holders of Voting
                  Securities immediately prior to such sale or transfer;

                        (E)   the Company and its subsidiaries, in any
                  transaction or series of related transactions, sells or
                  otherwise transfers business operations that generated two
                  thirds or more of the consolidated revenues (determined on the
                  basis of the Company's four most recently completed fiscal
                  quarters) of the Company and its subsidiaries immediately
                  prior thereto;

                        (F)   the Company files a report or proxy statement with
                  the Securities and Exchange Commission pursuant to the
                  Exchange Act disclosing that a change in control of the
                  Company has or may have occurred or will or may occur in the
                  future pursuant to any then existing contract or transaction;
                  or

                        (G)   any other transaction or series of related
                  transactions occur that have substantially the effect of the
                  transactions specified in any of the preceding clauses in this
                  paragraph (ii).

            Notwithstanding the provisions of Section 9(a)(ii)(A) or
9(a)(ii)(D), unless otherwise determined in a specific case by majority vote of
the Board of Directors of the Company, a Change of Control shall not be deemed
to have occurred for purposes of this Agreement solely because (i) the Company,
(ii) an entity in which the Company directly or indirectly beneficially owns 50%
or more of the voting securities or (iii) any Company sponsored employee stock
ownership plan, or any other employee benefit plan of the Company, either files
or becomes obligated to file a report or a proxy statement under or in response
to Schedule 13D, Schedule 14D-1, Form 8-K or Schedule 14A (or any successor
schedule, form or report or item therein) under the Exchange Act, disclosing
beneficial ownership by it of shares of stock of the Company, or because the
Company reports that a Change in Control of the Company has or may have occurred
or will or may occur in the future by reason of such beneficial ownership.

            (b)   Claim: any threatened, pending or completed action, suit,
proceeding or alternative dispute resolution mechanism, or any inquiry, hearing
or investigation whether conducted by the Company or any other party, whether
civil, criminal, administrative, investigative or other.

            (c)   Expenses: include attorneys' fees and all other costs, fees,
expenses and obligations of any nature whatsoever paid or incurred in connection
with investigating, defending, being a witness in or participating in (including
appeal), or preparing to defend, be a witness in or participate in any Claim
relating to any Indemnifiable Event.

            (d)   Indemnifiable Event: any event or occurrence (whether before
or after the date hereof) related to the fact that Indemnitee is or was a
director, officer, employee, consultant,

                                        8

<PAGE>

agent or fiduciary of or to the Company, or any subsidiary of the Company, or is
or was serving at the request of the Company as a director, officer, employee,
trustee, agent or fiduciary of another corporation, partnership, joint venture,
employee benefit plan, trust or other enterprise, or by reason of anything done
or not done by Indemnitee in any such capacity.

            (e)   Potential Change in Control: shall be deemed to have occurred
if (i) the Company enters into an agreement, the consummation of which would
result in the occurrence of a Change in Control; (ii) any person (including the
Company) publicly announces an intention to take or to consider taking actions
which, if consummated, would constitute a Change in Control; (iii) any person,
other than a trustee or other fiduciary holding securities under an employee
benefit plan of the Company or a corporation owned, directly or indirectly, by
the stockholders of the Company in substantially the same proportions as their
ownership of stock of the Company, who is or becomes the beneficial owner,
directly or indirectly, of securities of the Company representing 9.5% or more
of the combined voting power of the Company's then outstanding Voting
Securities, increases such person's beneficial ownership of such securities by
five percentage points or more over the initial percentage of such securities;
or (iv) the Board of Directors of the Company adopts a resolution to the effect
that, for purposes of this Agreement, a Potential Change in Control has
occurred.

            (f)   Reviewing Party: (i) the Company's Board of Directors
(provided that a majority of directors are not parties to the particular Claim
for which Indemnitee is seeking indemnification) or (ii) any other person or
body appointed by the Company's Board of Directors, who is not a party to the
particular Claim for which Indemnitee is seeking indemnification, or (iii) if
there has been a Change in Control, the special independent counsel referred to
in Section 2 hereof.

            (g)   Voting Securities: any securities of the Company which vote
generally in the election of directors.

            Section 10. Amendments, Termination and Waiver. No supplement,
modification, amendment or termination of this Agreement shall be binding unless
executed in writing by both of the parties hereto. No waiver of any of the
provisions of this Agreement shall be deemed or shall constitute a waiver of any
other provisions hereof (whether or not similar) nor shall such waiver
constitute a continuing waiver.

            Section 11. Contribution. If the indemnification provided in
Sections 1 and 3 of this Agreement is unavailable, then, in respect of any Claim
in which the Company is jointly liable with Indemnitee (or would be if joined in
the Claim), the Company shall contribute to the amount of Expenses, judgments,
fines, penalties and amounts paid in settlement as appropriate to reflect: (i)
the relative benefits received by the Company, on the one hand, and Indemnitee,
on the other hand, from the transaction from which the Claim arose, and (ii) the
relative fault of the Company, on the one hand, and of Indemnitee, on the other,
in connection with the events which resulted in such Expenses, judgments, fines,
penalties and amounts paid in settlement, as well as any other relevant
equitable considerations. The relative fault of the Company, on the one hand,
and of Indemnitee, on the other, shall be determined by reference to, among
other things, the

                                        9

<PAGE>

parties' relative intent, knowledge, access to information and opportunity to
correct or prevent the circumstances resulting in such Expenses and Liabilities.
The Company agrees that it would not be just and equitable if contribution
pursuant to this Section 11 were determined by pro rata allocation or any other
method of allocation which does not take account of the equitable considerations
described in this Section 11.

            Section 12. Subrogation. In the event of payment under this
Agreement, the Company shall be subrogated to the extent of such payment to all
of the rights of recovery of Indemnitee, who shall execute all papers required
and shall do everything that may be necessary to secure such rights, including
the execution of such documents necessary to enable the Company effectively to
bring suit to enforce such rights.

            Section 13. No Duplication of Payments. The Company shall not be
liable under this Agreement to make any payment in connection with any Claim
made against Indemnitee to the extent Indemnitee has otherwise actually received
payment (under insurance policy, Certificate of Incorporation or otherwise) of
the amounts otherwise indemnifiable hereunder.

            Section 14. Binding Effect, Etc. This Agreement shall be binding
upon and inure to the benefit of and be enforceable by the parties hereto and
their respective successors, assigns, including any direct or indirect successor
by purchase, merger, consolidation or otherwise to all or substantially all of
the business and/or assets of the Company, spouse, heirs, and personal and legal
representatives. This Agreement shall continue in effect regardless of whether
Indemnitee continues to serve as a director or officer (or in one of the
capacities enumerated in Section 9(d) hereof) of the Company or of any other
enterprise at the Board of Director's request.

            Section 15. Severability. The provisions of this Agreement shall be
severable in the event that any of the provisions hereof (including any
provision within a single section, paragraph or sentence) are held by a court of
competent jurisdiction to be invalid, void or otherwise unenforceable, and the
remaining provisions shall remain enforceable to the fullest extent permitted by
law.

            Section 16. Applicable Law and Consent to Jurisdiction. This
Agreement and the legal relations among the parties shall be governed by, and
construed and enforced in accordance with, the laws of the State of Delaware,
without regard to its conflict of laws rules. The Company and Indemnitee hereby
irrevocably and unconditionally (i) agree that any action or proceeding arising
out of or in connection with this Agreement shall be brought only in the
Delaware Court and not in any other state or federal court in the United States
of America or any court in any other country, (ii) consent to submit to the
exclusive jurisdiction of the Delaware Court for purposes of any action or
proceeding arising out of or in connection with this Agreement, (iii) appoint,
irrevocably, to the extent such party is not a resident of the State of Delaware
Registered Agents and Incorporators, L.L.C., 411 Jaymar Boulevard, Newark,
County of New Castle, DE 19702 as its agent in the State of Delaware as such
party's agent for acceptance of legal process in connection with any such action
or proceeding against such party

                                       10

<PAGE>

with the same legal force and validity as if served upon such party personally
within the State of Delaware, (iv) waive any objection to the laying of venue of
any such action or proceeding in the Delaware Court, and (v) waive, and agree
not to plead or to make, any claim that any such action or proceeding brought in
the Delaware Court has been brought in an improper or inconvenient forum.

            Section 17. Identical Counterparts. This Agreement may be executed
in one or more counterparts, each of which shall for all purposes be deemed to
be an original but all of which together shall constitute one and the same
Agreement. Only one such counterpart signed by the party against whom
enforceability is sought needs to be produced to evidence the existence of this
Agreement.

            Executed this ______ day of _____________, 200__.

                                          Micrus Corporation

                                          By: __________________________________

                                              Name: ____________________________

                                              Title: ___________________________

                                          By: __________________________________
                                              Indemnitee

                                       11exv10w15

 

Exhibit 10.15

***Certain confidential information contained in this document, marked by brackets, has been
omitted and filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the
Securities Exchange Act of 1934, as amended.

AMENDED AND RESTATED DISTRIBUTION AGREEMENT

This Amended and Restated Distribution Agreement (“Agreement”) is made as of this 1st day of
November, 2004 by and between: MICRUS CORPORATION, a Delaware corporation, having a principal place
of business at 610 Palomar Avenue, Sunnyvale, California 94085, United States , and its
subsidiaries (collectively “Micrus”) and NEUROLOGIC (UK) LIMITED, a company organized under the
laws of the United Kingdom, and having a principal place of business at Albreda House, Lydgate
Lane, Sheffield, S10 5FH, United Kingdom (“Distributor”).

     WHEREAS, Micrus has developed implantable, three-dimensional microcoils and related accessory
products to be used in the Field, as hereinafter defined, and may develop other products for use in
the Field; and

     WHEREAS, Distributor has substantial experience in marketing medical products and desires to
distribute the Products, as hereinafter defined, in the territory of [***];

     WHEREAS, Micrus is willing to use Distributor as its exclusive distributor of the Products for
use in the Field, in the territory of [***], subject to the terms and conditions of this Agreement;
and

     WHEREAS, Micrus and Neurologic UK have entered into a Distribution Agreement dated as of May
1, 2000 (the “Original Agreement”) and wish to amend and restate the Original Agreement in its
entirely as set forth below.

     NOW THEREFORE, in consideration of the premises and the mutual covenants herein recited, and
other good and valuable considerations, the receipt of which is acknowledged, it is agreed as
follows:

ARTICLE I — DEFINITIONS

     As used in this Agreement, the following terms, whether used in the singular or plural, shall
have the meanings indicated:

     1.1 “Effective Date” shall mean April 1, 2004.

     1.2 “Field” shall mean the field of interventional neuroradiology, or such field(s)
as to which the parties may agree in writing.

     1.3 “Marketing Authorizations” shall mean all authorizations, licenses, approvals,
and registrations to import, market and distribute the Products in the Territory pursuant to the
terms of this Agreement, as may be required by an appropriate governmental agency, except any CE
Mark, which such mark shall be obtained and maintained by Micrus.

     1.4 “Product(s)” shall mean (a) the implantable, three-dimensional micro-coils,
together with a resistive heat-activated delivery device, developed, manufactured, or made
available to Distributor by Micrus, and (b) any other Micrus product which utilizes Micrus’
licensed, patented or proprietary micro-coil and related delivery device technology; both of the
foregoing (a) and (b) solely as used in the Field and as delivered to Distributor from time to time
by Micrus under this Agreement.

     1.5 “Territory” shall mean the geographic territories of [***].

***Confidential Treatment Requested.

 

 

ARTICLE II — APPOINTMENT OF DISTRIBUTOR

     2.1 Appointment of Distributor. Subject to the terms and conditions of this Agreement
(including, without limitation, Article VI), Micrus hereby appoints Distributor as its exclusive
distributor of the Product within the Territory. Distributor agrees that it shall not sell,
advertise, distribute or otherwise transfer or assist in the transfer of any product that competes
with the Product. Distributor may distribute the Product only as packaged by Micrus. Distributor
shall not sell, advertise, distribute, or otherwise transfer or assist in the transfer of the
Product outside the Territory or to persons or entities located outside the Territory, except that,
solely to the extent necessary to comply with the EEC Treaty (also known as the Treaty of Rome),
Distributor will not be prevented from distributing Products to persons or entities outside the
Territory who (i) are located and take delivery within the EEC, (ii) are not solicited by
Distributor (or any of Distributor’s associate distributors or sub-distributors pre-approved by
Micrus as set forth below), and (iii) approach Distributor (or any of Distributor’s associate
distributors or sub-distributors pre-approved by Micrus as set forth below) in the Territory on
their own initiative. Micrus reserves the right to grant similar distribution rights in the Product
to third parties for distribution and sale outside of the Territory; provided,
however, such third parties shall be prohibited from selling or distributing the Product
within the Territory during the term of this Agreement. Distributor has no authority to appoint an
associate distributor or sub-distributor of the Product without the prior written authorization of
Micrus. If such authorization is given, each such distributor or sub-distributor shall be bound in
writing to restrictions at least as strict as those restrictions imposed on Distributor under this
Agreement.

     2.2 Relationship of Parties. The relationship of Micrus and Distributor established
by this Agreement is that of independent contractors, and nothing contained in this Agreement shall
be construed to: (i) give either party the power to direct or control the day-to-day activities of
the other; or (ii) allow Distributor to create or assume any obligation on behalf of Micrus for any
purpose whatsoever. All financial obligations associated with Distributor business are the sole
responsibility of Distributor. All sales and other agreements between Distributor and its customers
are Distributor’s exclusive responsibility and shall have no effect on Distributor’s or Micrus’
obligations under this Agreement.

     2.3 Marketing Authorizations.

          2.3.1 Micrus Obligations. Micrus shall deliver to Distributor all scientific,
clinical, toxicological, and manufacturing data in the possession of Micrus and necessary to obtain
all required Marketing Authorizations within the Territory, provided Distributor maintains all such
data as confidential pursuant to Article VII.

          2.3.2 Distributor Obligations. At its own expense, Distributor shall use its best
efforts to obtain all necessary Marketing Authorizations within the Territory. Specifically,
Distributor agrees that it will undertake to manage, at Distributor’s expense, all animal trials
and human clinical trials required to obtain the Marketing Authorizations. These approvals will be
obtained jointly in the name of Micrus and Distributor. Upon termination of this Agreement,
Distributor agrees to transfer all of its rights, title and interest in and to such approvals to
Micrus, or any third party as may be designated in writing by Micrus. Distributor shall provide
Micrus with written quarterly progress reports of its efforts to obtain Marketing Authorizations.
Distributor agrees not to sell or distribute the Product in any geographic region within the
Territory until such time as all Marketing Authorizations in such geographic region have duly been
obtained, and to act at all times in a manner consistent with such Marketing Authorizations.

2

 

     2.4 Trademarks 

          2.4.1 License. Micrus hereby grants to Distributor the non-transferable,
non-assignable, non-sublicensable right and license to use its trademarks, service marks, and
tradenames that Micrus may adopt from time to time (the “Trademarks”) solely on or in connection
with Distributor’s promotion, sale and distribution of the Product within the Territory as
authorized under this Agreement for the term of this Agreement. Distributor shall have the right to
indicate to the public that it is an authorized distributor of the Product. Distributor shall not
alter or remove any Trademark applied to the Product. Nothing herein shall grant to Distributor any
right, title or interest in the Trademarks. All use of the Trademarks, and will goodwill associated
therewith, shall inure to the benefit of Micrus. At no time during or after the term of this
Agreement shall Distributor challenge or assist others to challenge the Trademarks or the
registration thereof or attempt to register any trademarks, marks or trade names confusingly
similar to those of Micrus.

          2.4.2 Approval of Representations. Distributor shall respect the Trademarks and follow
the instructions of Micrus as to all usage of the Trademarks, including, without limitation,
complying with Micrus’ quality control requirements and submitting samples of Distributor’s use of
the Trademarks to Micrus for approval. If any of the Trademarks are to be used in conjunction with
any other mark on or in relation to the Product, then the Trademark shall be presented equally
legibly, equally prominently, and of the same or greater size than the other mark(s) but
nevertheless separated from the other trademark so that each appears to be a mark in its own right,
distinct from the other mark(s).

     2.5 Provision of Data. Distributor agrees to provide Micrus promptly with all
clinical and technical information and data with respect to the Product which it develops during
the term of this Agreement. Distributor further agrees to communicate promptly to Micrus any and
all modifications, design changes or improvements to the Products suggested by any of Distributor’s
customers, distributors, employees or agents. Distributor further agrees that Micrus shall have,
and is hereby assigned, any and all right, title and interest in and to any such suggested
modifications, design changes or improvements to the Products without the payment of any additional
consideration therefor either to Distributor or its customers, distributors, employees or agents.
Distributor will also promptly notify Micrus of any infringement of any of the Trademarks, patent
or other proprietary rights relating to the Products of which Distributor becomes aware.

ARTICLE III — PURCHASE OF PRODUCT

     3.1 Terms and Conditions. All purchases of Product by Distributor from Micrus during
the term of this Agreement shall be subject to the terms and conditions of this Agreement.

     3.2 Prices.

          3.2.1 Subject to this Section 3.2, Micrus will sell Product to Distributor at the preferential
prices shown in Exhibit A (“Purchase Price”) until [***] after the Effective Date or until such
time the pricing is revised in accordance with this Agreement, whichever is earlier. The parties
agree to discuss, in good faith, increases and revisions to the prices, within at least [***] from
the Effective Date of this Agreement, based on [***] and as relevant. The differences between the
Purchase Price and Distributor’s selling price to its customers shall be Distributor’s sole
remuneration for sale of the Product. Distributor shall have sole discretion to establish the
resale price of the Product to third parties subject only to any regulatory or governmental
limitations.

          3.2.2 The Purchase Price shall be revised [***], and at such other times as the parties may
agree in writing. Such revisions shall apply to all orders for the affected Product received after
the effective date of revision. [***]

     3.2.3 All prices are [***].

***Confidential Treatment Requested.

3

 

     3.3 Taxes. The Purchase Price will be net of any Distributor federal, state or local
taxes that may be applicable to the Product. When Micrus has the legal obligation to collect such
taxes, the appropriate amount shall be added to Distributor’s invoice and paid by Distributor,
unless Distributor provides Micrus with a valid tax exemption certificate authorized by the
appropriate taxing authority. Micrus agrees to pay any United States federal, state or local taxes,
duties or other governmental assessments that may be required to ship Product to Distributor.

     3.4 Order and Acceptance. All orders for Product submitted by Distributor shall be
initiated by written purchase orders sent to Micrus via a method set forth in Section 11.5 and
requesting a delivery date during the term of this Agreement; provided, however, that an order may
initially be placed orally, by telefax or by e-mail if a confirming written purchase order is
received by Micrus within [***] after said oral, telefax or e-mail order. To facilitate Micrus’
production scheduling, Distributor shall submit purchase orders to Micrus at least [***] prior to
the first day of the requested month of delivery. No order shall be binding upon Micrus until
accepted by Micrus in writing, and Micrus shall have no liability to Distributor with respect to
purchase orders that are not so accepted. Micrus shall either: (i) notify Distributor, in writing,
of the acceptance or rejection of an order (or any portion thereof) and of the assigned delivery
date for accepted orders with [***] of receipt of the purchase order; or (ii) send Product pursuant
to such accepted order. No partial fulfillment of an order shall constitute a commitment to fulfill
the entire order, absent the written acceptance of such entire order. Micrus shall use its
commercially reasonable efforts to deliver Product at the time specified in its written acceptance
of Distributor’s purchase orders. Micrus reserves the right at any time to discontinue the
manufacture, supply or sale of any Product, to make changes in materials or design, or to add
improvements to any Product, without incurring any liability whatsoever.

     3.5 Terms of Purchase Orders. Distributor’s purchase orders submitted to Micrus from
time to time with respect to Product to be purchased hereunder shall be governed by the terms of
this Agreement, and nothing contained in any such purchase order shall in any way modify such terms
of purchase or add any additional terms or conditions.

     3.6 Payment. Micrus shall submit an invoice to Distributor upon each shipment of
Product ordered by Distributor. The invoice shall set forth the Purchase Price for the Product in a
given shipment plus any freight, taxes or other applicable costs initially paid by Micrus but to be
borne by Distributor. Payment shall be made by Distributor by wire transfer, check or other
instrument approved in writing by Micrus. Payment terms shall be the full invoiced amount to be
paid by Distributor to Micrus within [***] of the date of the invoice; which payment terms shall be
reviewed after the first year of this Agreement for payment terms applicable to subsequent years of
the then-current term of the Agreement; provided, however, that any revision to the payment terms
must be made by a mutually agreed to writing executed by both parties. Any invoiced amount not
received within [***] of the date of invoice shall be subject to a service charge of [***], or if
lower, the maximum interest rate allowed by law. Distributor shall pay all of Micrus’ costs and
expenses (including reasonable attorney’s fees) to enforce and preserve Micrus’ rights under this
Subsection 3.6. If at any time an outstanding invoice for Product shipped to Distributor becomes
unpaid and outstanding for greater than [***], at Micrus’ option, Micrus may require that
Distributor effect payment by means of an irrevocable letter of credit drawn on a bank approved by
Micrus; the letter of credit shall be upon terms acceptable by Micrus, shall allow for partial
shipment, and shall be in an amount equal to Distributor’s purchase price for the Product plus all
applicable taxes, shipping charges, and other charges to be borne by Distributor. All exchange,
interest, banking collection and other charges shall be at Distributor’s expense.

***Confidential Treatment Requested.

4

 

     3.7 Quarterly Reports. Within forty-five (45) days after the end of each quarter,
Distributor shall provide Micrus with a written sales breakdown, including without limitation, the
amount and type of Product, and names of end users of the Product sold during the period.

ARTICLE IV — SUPPLY OF PRODUCT

     4.1 Terms of Distributor Requirements. Subject to the terms and conditions of this
Agreement (including, without limitation, Section 3.4), Micrus agrees to sell and Distributor
agrees to purchase from Micrus Distributor’s entire requirements of products of the type provided
by Micrus under this Agreement, solely for distribution and/or sale in the Territory. Micrus shall
use commercially reasonable efforts to manufacture the Product and, subject to Section 3.4, supply
them to Distributor in quantities sufficient to satisfy Distributor’s needs in accordance with the
provisions of this Article IV, provided Distributor submits to Micrus purchase estimates pursuant
to Section 4.2.

     4.2 Purchase Estimates. Distributor shall submit to Micrus, beginning ninety (90) days
before the first anticipated order of Product and within the first ten (10) days after the
beginning of each calendar quarter thereafter, a non-binding good faith estimate of the amount of
Product to be required and purchased by Distributor for both the next three months and the next
twelve-month periods.

     4.3 Inspection and Dispute Resolution Relating to Satisfaction of Product
Specifications. The following provisions relate to inspection and resolution of disputes:

          4.3.1 Rejection of Product. Distributor shall inspect all Product promptly upon
receipt thereof and may reject any Product pursuant to this Section 4.3.1 that fails to meet the
specifications set forth in Micrus’ current product specifications for the Product. Any Product not
properly rejected within thirty (30) days of receipt of that Product at Distributor’s facility
after customs clearance for import (the “Rejection Period”) shall be deemed accepted. To reject a
Product, Distributor shall within the Rejection Period, (i) notify Micrus in writing by telefax or
by mail (with confirmation of transmission) of its rejection and the reason for the rejection, and
(ii) return, at its expense, the rejected Product to Micrus (the “Returned Product”) in the same
condition in which it was delivered to Distributor. All claims made by Distributor after its
inspection of the Product shall be handled on a case-by-case basis during which time Micrus shall
have the right to first inspect any Product involved before being required to take any action with
respect thereto. Micrus shall make its investigation within thirty (30) days of receipt of notice
of a claim from Distributor. Micrus shall, at its expense, replace Product it determines to be
defective and ship such replacement Product freight prepaid. In no event shall Micrus be liable
under this Agreement for any failure of any Product to meet the specifications due to modification
or improper use, storage or shipment of the Product by Distributor or anyone receiving the Product
from or on behalf of Distributor.

          4.3.2 Resolution of Disputes Relating to Product Specifications. If the parties hereto
fail to agree as to whether a delivered quantity of Product meets its agreed specifications, then
the parties shall cooperate to have the Product in dispute analyzed by a jointly selected qualified
independent testing laboratory.

          4.3.3 Return of Product After Rejection Period. After the Rejection Period, Micrus’
limited warranty as stated in Section 8.1 hereof shall be applied. If Micrus tests and inspects the
Returned Product and determines that such Returned Product (i) has been physically damaged, (ii)
has been modified or improperly used, stored or shipped by Distributor or anyone receiving the
Product from or on behalf of Distributor, or (iii) performs according to Micrus’ written
specifications, no credit will be given to Distributor. If upon such test and inspections such
Returned Product (a) has not been physically damaged, (b) has not been modified or improperly used,
stored or shipped by Distributor or anyone receiving the Product from or on behalf of Distributor,
and (c) does not perform to Micrus’ written specifications, these Returned Products will be
replaced at no cost to
Distributor. In all cases of physical damage or modification to, or improper use, storage or
shipment of, Returned Product, no credit will be given to Distributor.

5

 

     4.4 Title. Title and risk of loss pass to Distributor when Product leaves Micrus’
manufacturing facility. Distributor shall be solely responsible for the payment of all freight and
insurance and other costs, expenses, fees, duties, imports, and charges of whatever kind or nature
arising from the shipment, delivery, and importation of Product into the Territory. Distributor
shall solely be responsible for taking all actions necessary to obtain clearance to import Product
into the Territory and Distributor warrants that it will comply in all respects with any
restrictions set forth in the export license for every Product purchased hereunder.

     4.5 Reporting. Distributor agrees to report to Micrus any information from any
source, including, without limitation, employees, distributors, agents, customers, user facilities,
individuals, or medical or scientific literature, whether published or unpublished, that reasonably
suggests that there is a problem with the Product or a probability that the Product or a similar
product has caused or contributed to a death, serious illness or serious injury, including but not
limited to, severe or permanent disability, stroke, or brain damage as promptly as possible but
within five (5) days of receipt of information of such event. Distributor agrees not to disclose
any such information referred to herein to any third party without the prior written consent of
Micrus.

          4.5.1 Serious illness means an event that is life threatening, results in permanent impairment
of a body function or permanent damage to the body structure, or necessitates immediate medical or
surgical intervention to preclude permanent impairment of a body function or permanent damage to a
body structure.

          4.5.2 Serious injury means an event that is life threatening, results in permanent impairment
of a body function or permanent damage to a body structure, or necessitates medical or surgical
intervention to preclude permanent impairment of a body function or permanent damage to a body
structure.

     4.6 Monitoring. Each of the parties hereto shall monitor all relevant journals and
media communications for information on factors materially affecting the use or efficacy of the
Product and shall promptly inform the other party of such information. The informing party may
provide in writing its evaluation of such information. Either party shall promptly inform the other
if it has actual knowledge of any measures which are necessary to eliminate or minimize any risk
associated with the use of the Product or a specific production lot of the Product.

ARTICLE V — ADDITIONAL OBLIGATIONS OF DISTRIBUTOR

     5.1 Marketing Obligations. Distributor agrees to use its best efforts to
successfully promote and distribute the Product, at its own expense, in the Territory using
diligent and vigorous efforts to maximize sales and market penetration at the earliest date. Such
efforts shall include, but are not limited to, preparing promotional materials, advertising the
Product in trade publications within the Territory, participating in appropriate trade shows within
the Territory, and directly soliciting orders from customers within the Territory for the Product.
Subject to Micrus’ approval and obligations under Article VIII hereof, Distributor shall also be
responsible for all quality control, lot release for Distributor’s requirements, promotional
activities, marketing and selling efforts, distribution and technical services. All promotional
materials developed by Distributor shall be submitted to Micrus for approval before such materials
are distributed by Distributor. Micrus shall promptly review such materials, and if no written
response is provided by Micrus within thirty (30) days after receipt of such material, then the
material will be deemed to have been approved by Micrus.

     5.2 Finances and Personnel. Distributor shall, at its sole cost, expense, and risk:
(i) employ on its own behalf an appropriate number of specialized, trained, and qualified sales
personnel whose main function shall be the promotion and sale of the Product in the Territory; and
(ii) maintain a suitable organization for the promotion and sale of the Products in the Territory
pursuant to Distributor’s obligations hereunder.

6

 

     5.3 Customer and Sales Reporting. Distributor shall, at its own expense and
consistent with the sales policies of Micrus:

          5.3.1 place the Product in Distributor’s catalogues as soon as possible and feature the
Product in any applicable trade show within the Territory that it attends;

          5.3.2 provide adequate contact with existing and potential customers within the Territory on a
regular basis, consistent with good business practice;

          5.3.3 assist Micrus in assessing customer requirements for the Product, including
modifications and improvements thereto, in terms of quality, design, functional capability, and
other features; and

          5.3.4 submit market research information, as reasonably requested by Micrus regarding
competition and changes in the market within the Territory.

     5.4  Marketing Plans. Distributor shall submit to Micrus for its approval a Product
launch plan for the Product in the Territory, and on or before October of each year, an annual
marketing and sales plan for the Product, Each of these plans shall include specific marketing
sales strategies, tactics and goals, market research analysis, promotion budgets, and sales
projections.

     5.5 Compliance with Laws. Distributor shall market and distribute the Product in the
Territory in compliance with all applicable laws and regulations and good commercial practice and
for uses and applications approved by Micrus in writing for the Product. Distributor shall comply
with all laws, rules and regulations as applicable to the marketing, distribution and sale of the
Product in the Territory or any part of it. Distributor further agrees to comply with the U.S.
Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”) and all applicable export laws,
restrictions and regulations of any U.S. or foreign agency or authority and not to export or
re-export or allow the export or re-export of the Product or any related technology or information
in violation of any such laws, restrictions or regulations. A copy of the FCPA is attached to this
Agreement as Appendix A.

     Distributor hereby declares that it has read and understood the provisions of the FCPA and, on
that basis, it further represents and covenants that neither it nor any of its employees or agents
have taken or will take any action to cause Distributor to be in violation of the FCPA.
Specifically, Distributor hereby certifies that it has not paid, nor offered or agreed to pay, nor
has caused to be paid, or offered or agreed to be paid, directly or indirectly, in respect of this
Agreement, any political contributions, fees or commissions to any public or governmental employee
or official anywhere for the purpose of influencing such official’s act or decision to provide
business to Distributor. Distributor further certifies that it will not, directly or indirectly,
in connection with this Agreement and the business resulting therefrom, offer, pay, promise to pay,
or authorize the giving of money or anything of value to any public or governmental employee or
official, to any political party or official thereof or to any candidate for political office, or
to any person, while knowing or being aware of a high probability that all or a portion of such
money or thing of value will be offered, given or promised, directly or indirectly, to any public
or government official, to any political party or official thereof, or to any candidate to
political office, for the purpose of: (a) influencing any act or decision of such official,
political party, party official, or candidate in his or its official capacity, including a decision
to fail to perform his or its official functions; or (b) inducing such official, political party,
party official or candidate to use his or its influence with the government or instrumentality
thereof to affect or influence any act or decision of such government or instrumentality, in order
to assist Micrus or Distributor in obtaining or retaining business for or with, or directing
business to any third party.

     Distributor agrees that if subsequent developments cause the certifications and information
reported herein to be no longer accurate or complete, Distributor will immediately so advise
Micrus. Distributor further agrees that its violation of any part of this Section 5.5 will be a
material breach of this Agreement and cause for
immediate termination, without further liability or obligation on the part of Micrus
notwithstanding anything to the contrary provided in this Agreement.

7

 

     Distributor shall obtain and bear all expenses relating to any necessary licenses and/or
exemptions with respect to the export from the United States of the Products to any location in
compliance with all applicable laws and regulations.

     5.6  Traceability. Distributor agrees to maintain access to records allowing Micrus
the ability to determine all customers who were shipped specific product lots. Product
Identification and traceability requirements are defined in ISO 9001 : 1994 (E) requirement 4.8 as
: “...the supplier shall maintain documented procedures for identifying the product from production,
delivery and installation.” Traceability in ISO 8402 Vocabulary is defined as : “ability to trace
the distribution and location of the product after delivery”.

ARTICLE VI — FAILURE TO MEET MINIMUM REQUIREMENTS

     In the event that in any given year, the total payments by Distributor under Section 3.6 do
not, in the aggregate, equal or exceed: [***] (“Minimum Purchase Requirements”), then Micrus may,
at its sole discretion, either: (a) convert the grant of the distribution rights pursuant to
Section 2.1 hereof to a non-exclusive basis; or (b) terminate this Agreement upon thirty (30) days
prior written notice to Distributor. If Micrus elects to convert the grant of distribution rights
to a non-exclusive basis, such election shall be made by delivery of written notice by Micrus to
Distributor and shall take effect on the [***].

ARTICLE VII — CONFIDENTIAL INFORMATION

     The parties hereto agree that each shall keep completely confidential and shall not publish or
otherwise divulge or use for its own benefit or for the benefit of any third party any information
of a proprietary nature furnished to it (the “Receiving Party”) by the other party (the “Disclosing
Party”) for a period of five (5) years after the termination of this Agreement without the prior
written approval of the disclosing party in each instance, except to the extent that it is
necessary to divulge such information for the obtaining of governmental approval for the marketing
of the Product and the Receiving Party discloses only the minimum of information necessary in
connection therewith and takes reasonable steps to maintain the confidentiality of such
information. Nothing in this Article 7 shall prevent disclosure or use of information: (i) already
known to the Receiving Party prior to its receipt of such information from the Disclosing Party;
(ii) which was known to the public at the time of disclosure, or subsequently becomes so known
through no act or omission of the Receiving Party; (iii) which is properly acquired by the
Receiving Party from a third party having the right to convey such information; or (iv) that is
required to be disclosed by law or regulation or in connection with any financing, acquisition,
merger or sale, provided the Receiving Party provides the Disclosing Party with advance notice of
such disclosure and takes reasonable steps to protect the confidentiality of such information.
Information of a proprietary nature shall include, but not be limited to, information concerning a
party’s products, proposed products, marketing plans, methods of manufacture, customers or any
other information or materials in whatever form not generally known to the public. Subject to the
foregoing, this specific terms of this Agreement (including all financial terms) shall be kept
confidential, however, the parties may refer generally to this Agreement and the parties’
relationship arising therefrom.

***Confidential Treatment Requested.

8

 

ARTICLE VIII — WARRANTY; LIMITATION OF LIABILITY

     8.1 Warranty. Micrus represents and warrants to Distributor that all Product
manufactured and delivered to Distributor pursuant to this Agreement shall meet Micrus’
specifications for such Product at the time of delivery by Micrus to Distributor for the shelf life
of the Product as specified on the Product labeling; provided, however, that such Product: (i) has
been shipped in accordance with Micrus’ shipping instructions and stored in accordance with the
instructions on the labeling and the packaging for such Product; (ii) is used in the application
for which it was intended; and (iii) has not been modified without Micrus’ prior written consent.
Distributor shall handle and be solely responsible for all warranty returns from its direct and
indirect customers. Micrus’ sole and exclusive liability under the warranty set forth in Section
8.1 shall be limited to a replacement to Distributor of the defective Product with a Product
substantially equivalent to the Product originally shipped by Micrus to Distributor.

     8.2 No Other Warranty. EXCEPT FOR THE EXPRESS WARRANTY SET FORTH IN SECTION 8.1
HEREIN, THE PRODUCT IS PROVIDED “AS IS,” AND MICRUS GRANTS NO OTHER WARRANTIES, EXPRESS OR IMPLIED,
BY STATUTE OR OTHERWISE, REGARDING ANY PRODUCT, ITS FITNESS FOR ANY PARTICULAR PURPOSE, ITS
QUALITY, ITS MERCHANTABILITY, OR OTHERWISE.

     8.3 Limitation of Liability: NOTWITHSTANDING ANYTHING ELSE IN THIS AGREEMENT OR
OTHERWISE, IN NO EVENT SHALL MICRUS BE LIABLE TO DISTRIBUTOR OR ANY OTHER PERSON OR ENTITY WITH
RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT UNDER ANY CONTRACT, NEGLIGENCE, STRICT LIABILITY OR
OTHER LEGAL OR EQUITABLE THEORY FOR (A) THE COST OF PROCUREMENT OF SUBSTITUTE GOODS, (B) ANY
SPECIAL, CONSEQUENTIAL, PUNITIVE, INDIRECT OR INCIDENTAL DAMAGES OR (C) LOST PROFITS OR LOST
BUSINESS; EVEN IF THE REMEDIES PROVIDED FOR IN THIS AGREEMENT FAIL OF THEIR ESSENTIAL PURPOSE AND
EVEN IF EITHER PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES; PROVIDED, HOWEVER, THAT
NOTHING HEREIN SHALL RELIEVE MICRUS FROM ANY PRODUCT LIABILITY CLAIM, AS SET FORTH IN ARTICLE IX
HERETO.

     8.4 Ownership. Distributor acknowledges and agrees that as between Distributor and
Micrus, Micrus owns all right, title and interest in and to all clinical, technical, product,
sales, marketing, and customer information and data with respect to the Product (including, without
limitation, any and all modifications, design changes or improvements relating thereto), and all
industrial and intellectual property rights of any kind in relation to the Product (including,
without limitation, any and all modifications, design changes or improvements relating thereto) or
any of the foregoing, including, without limitation, the right to patents, registered or other
designs, trademarks, trade names, inventions, copyright, know-how and any other confidential
information. Nothing contained in this Agreement shall be effective to give Distributor any rights
of ownership in or to any of the foregoing. To the extent Distributor owns any rights, title or
interest in or to the foregoing, Distributor hereby assigns all of such rights to Micrus. The
provision of Product technical information to Distributor under this Agreement is for the sole
purpose of obtaining approval from the regulatory authorities in the Territory for the Product and
is subject to the confidentiality obligations set forth in Article VII. The use by Distributor of
any of these property rights is authorized only for the purposes herein set forth, and upon
termination of this Agreement for any reason such authorization shall cease.

     8.5 Sale Conveys No Right to Manufacture or Copy. The Product is offered for sale
and is sold by Micrus subject in every case to the condition that such sale does not convey any
license, expressly or by implication, to manufacture, duplicate or otherwise copy or reproduce the
Product or any portion thereof. Distributor shall take appropriate steps with its customers and
distributors, if any, as Micrus may request, to inform them of and assure compliance with the
restrictions contained in this Section 8.5.

9

 

ARTICLE IX — INDEMNIFICATION

     9.1 Indemnification by Micrus. Micrus agrees to and hereby does indemnify and hold
Distributor harmless from and against all claims, damages, losses, costs and expenses, including
reasonable attorneys’ fees, which Distributor may incur by reason of any Product sold or furnished
by Micrus which result in injury, illness, or death of any person, to the extent that such claims
arise out of or result from either the negligence or willful misconduct of Micrus in: (i) product
design; or (ii) manufacturing; or (iii) breach of any representations or warranties by Micrus
hereunder, except if such claims arise from the negligence or willful misconduct of Distributor,
any modification of the Product other than by Micrus or any breach by Distributor of any of its
obligations, representations or warranties under this Agreement. Micrus shall have sole control of
any such action or settlement negotiations, and Micrus agrees to pay, subject to the limitations
hereinafter set forth, any final judgment entered against Distributor or its customer on such issue
in any such suit or proceedings indemnified hereunder by Micrus. Distributor agrees to notify
Micrus promptly in writing of such claim, suit or proceeding and gives Micrus authority to proceed
as contemplated herein, and, at Micrus’ expense, give Micrus proper and full information and
assistance to settle and/or defend any such claim, suit or proceeding. If the Product, or any part
thereof, is the subject of any claim, suit or proceeding for infringement of any third party
patents or trademark in the United States or in the Territory, or if the sale or use of the
Product, or any pan thereof, is, as a result thereof, enjoined, then Micrus shall, at its option
and expense: (a) procure for Distributor and its customers the right under such patent, or
trademark to sell or use, as appropriate, the Product or such part thereof; or (b) replace the
Product, or part thereof, with other suitable Product or parts; or (c) suitably modify the Product,
or part thereof, or (d) if the use of the Product, or part thereof, is prevented by injunction,
remove the Product or part thereof, and refund the aggregate payments paid therefore by
Distributor, less a reasonable sum for the use and damage; provided that such claim, suit or
proceeding is not based on a modification of the Product by Distributor or anyone other than
Micrus, or a combination of the Product with any product other than those provided by Micrus for
use with the Product.

     9.2 Indemnification by Distributor. Distributor hereby agrees to and hereby does
indemnify and hold Micrus harmless from and against all claims, damages, losses, costs and
expenses, including reasonable attorneys’ fees, which Micrus may incur to the extent that such
claims arise out or result from; (i) the unlawful sale or other distribution of Product by
Distributor, including any improper sales by Distributor to customers who are located outside the
Territory; (ii) the negligent or willful misconduct of Distributor in the distribution, labeling or
packaging of the Product; (iii) Distributor’s recommended use of Product in violation of this
Agreement; (iv) modification of the Product by Distributor, (v) combination of the Product with any
product other than those provided by Micrus for use with the Product, or (vi) breach of any
representation, warranty, or obligation by Distributor hereunder, except for such claims which
arise out of or result from the gross negligence, or willful misconduct of Micrus. Distributor
shall have sole control of any such action or settlement negotiations, and Distributor agrees to
pay, subject to the limitations hereinafter set forth, any final judgment entered against Micrus or
its customer on such issue in any such suit or proceedings defended by Distributor. Micrus agrees
to notify Distributor promptly in writing of such claim, suit or proceeding and gives Distributor
authority to proceed as contemplated herein, and, at Distributor’s expense, give Distributor proper
and full information and assistance to settle and/or defend any such claim, suit or proceeding.

     9.3 Contribution. In the event the negligence of Distributor and Micrus contribute
to any loss, cost, damages, claim or expense relating to Product supplied and/or distributed or
sold hereunder, then Distributor and Micrus shall be responsible for that portion of the loss,
cost, damages, claim or expense to which its negligence contributed.

10

 

ARTICLE X — TERM AND TERMINATION

     10.1 Term. This Agreement shall commence on the Effective Date and shall continue in
force for a fixed term until [***], unless terminated earlier under the provisions of this
Agreement. At the end of the fixed term, this Agreement shall be automatically renewed on the same
terms and conditions for an additional [***]period, unless earlier terminated under the provisions
hereof or unless one party gives to the other notice of its intention to terminate at least [***]
prior to the expiration of the fixed term hereof or of any renewal period.

     10.2 Failure to Make Payment. Micrus may terminate this Agreement at any time upon
Distributor’s failure to make payments due to Micrus pursuant to this Agreement and the
continuation of such failure for more than thirty (30) days after delivery of written notice to
Distributor of such failure.

     10.3 Failure to Commercialize or Obtain Marketing Authorizations. Micrus may
terminate this Agreement at any time upon Distributor’s failure to use diligent efforts to move
ahead with its obligations to market, sell and distribute Product under Section 5.1 or meet the
Minimum Purchase Requirement and upon the continuation of such failure for more than ninety (90)
days after delivery of written notice to Distributor of such failure, except where such failure of
Distributor is a result of the failure of Micrus to meet its obligations as defined in this
Agreement or due to circumstances beyond the reasonable control of Distributor pursuant to Section
11.7 hereof.

     10.4 Patent. Copyright. Trademark Violations. Micrus may terminate this Agreement at
any time without notice upon Distributor’s violation of Sections 8.4 or 8.5 hereof.

     10.5 Material Breach. Except as set forth in Section 5.5 hereof, either party may
terminate this Agreement upon ninety (90) days prior written notice in the event of the other
party’s breach of any other material provision of this Agreement, if such default or breach is not
remedied within ninety (90) days from the date of such notice, except where such default or
breach is due to circumstances beyond the reasonable control of the other party pursuant to Section
11.7 hereof, or as otherwise specified in this Article X.

     10.6 Bankruptcy. If, during the term of this Agreement, either party makes an
assignment, of this Agreement or generally, for the benefit of creditors, or becomes insolvent or
seeks protection under any bankruptcy, receivership, trust deed, creditor’s arrangement or
composition, or if any comparable proceeding is instituted against the other party and is not
dismissed within ninety (90) days of such institution, then the other party may terminate this
Agreement immediately upon delivery of written notice thereof.

     10.7 Control Event. In the event that Distributor sells all or substantially all of
its business or assets to which this Agreement relates to a non-affiliate, or has more than fifty
percent (50%) of its equity securities purchased by a single purchaser who is a
non-affiliate in one transaction (a “Control Event”) (whether by sale, acquisition, merger,
operation of law or otherwise), then Micrus may terminate this Agreement with thirty (30) days
prior written notice at any time after the occurrence of the Control Event. In the event that
Micrus sells all or substantially all of its business or assets to which this Agreement relates to
a non-affiliate, or has more than fifty percent (50%) of its equity securities purchased by a
purchaser who is a non-affiliate in one transaction, then Micrus may terminate this Agreement at
any time, provided Micrus pays Distributor a termination fee of [***] for the then current term.
For purposes of this section, a non-affiliate is not a parent, subsidiary or a subsidiary of a
common parent or a successor.

     10.8 Waiver. Any failure to terminate shall not be construed as a waiver by the
aggrieved party of its right to terminate for future defaults or breaches.

***Confidential Treatment Requested.

11

 

     10.9 Effects of Termination.

          10.9.1 Return of Property. Upon termination of this Agreement for any reason, each
party shall upon the request of the other party return all books, records, documents, data and
proprietary information which it shall have received from the other party pursuant to this
Agreement and which it shall still have in its possession or control; provided, however, that a
single copy may be retained solely for legal archival purposes by each party, subject to the
confidentiality provisions of Article VII.

          10.9.2 Accrued Payments. Termination of this Agreement by either party shall not
prejudice the right of either party to recover any payments for Products shipped under this
Agreement, and shall not prejudice any cause of action or claim of either party accruing under this
Agreement.

          10.9.3 Marketing and Distribution Rights. Upon termination of this Agreement,
Distributor’s rights to market, distribute, sell and otherwise transfer the Product, and all other
rights under this Agreement, shall immediately cease. The parties shall undertake to negotiate in
good faith a mutually acceptable agreement to satisfy any contractual obligations of Distributor to
supply the Product to third parties, and Micrus shall supply all necessary inventory under such
agreements. Except as needed to satisfy any contractual obligations existing as of the effective
date of termination and as approved by Micrus in writing, Distributor shall return all inventory in
its possession or control to Micrus in the same condition in which it was provided by Micrus within
sixty (60) days after termination.

          10.9.4 Marketing Authorizations. Upon termination of this Agreement, Distributor shall
promptly assign or otherwise transfer to Micrus or its designees all of Distributor’s rights, title
and interest in and to the Marketing Authorizations and/or pending applications for the Product;
provided, however, if such termination does not result from a breach of this Agreement by
Distributor, Micrus shall reimburse Distributor for its costs incurred in obtaining such Marketing
Authorizations.

          10.9.5 Trademark. Upon termination of this Agreement, the license to use the
Trademarks granted in Section 2.4 shall also terminate and all right, title and interest in such
Trademarks shall belong to Micrus.

          10.9.6 Pending Orders. Upon termination of this Agreement, Micrus shall have the
right, at its option, to continue or terminate any order pending as of the effective date of
termination.

          10.9.7 No Liability for Termination. Neither party will incur any liability whatsoever
for any damages, loss or expenses of any kind suffered or incurred by the other party (or for any
compensation to the other party) arising from or incident to any termination of this Agreement
pursuant to such party’s right of termination under this Agreement, whether or not such party is
aware of any such damages, loss or expenses.

          10.10 Termination Not Sole Remedy. Termination is not the sole remedy under this
Agreement and, whether or not termination is effected, all other remedies will remain available.

ARTICLE XI — GENERAL PROVISIONS

     11.1 Governing Law. This Agreement shall be governed by and interpreted in accordance
with the laws of the State of California and the United States of America, as though all parties
were resident of, and the contract was performed solely in, California without reference to
conflicts of laws rules thereof and without regard to the United Nations Convention on Contracts
for the International Sale of Goods. Except as set forth in Section 11.2, the sole jurisdiction and
venue for actions relating to the subject matter of this Agreement shall be the California state
and U.S. federal courts having jurisdiction in Santa Clara County, California, and the parties
hereby consent to the jurisdiction of such courts.

12

 

     11.2 Arbitration. Except for actions seeking injunctive relief, all disputes,
controversies, or differences which may arise between the parties hereto, out of, in relation to,
or in connection with this Agreement or the breach thereof, shall be finally settled by binding
arbitration in San Francisco, California, U.S.A., in accordance with the Commercial Arbitration
rules of the American Arbitration Association by one (1) arbitrator appointed in accordance with
such Rules, by which each party hereto agrees to be bound. Judgment upon an award rendered may be
entered in any court having jurisdiction, or application may be made to such court for judicial
acceptance of the award and an order of enforcement, as the case may be.

     11.3 Entire Agreement. This Agreement represents the entire Agreement and
understanding of the parties hereto with respect to the marketing and distribution of the Product
and the subject matter of this Agreement, and supersedes all previous agreements and understandings
related thereto, including without limitation the Original Agreement, and may only be amended or
modified in writing signed by an authorized representative of the parties hereto.

     11.4 Assignment. Distributor may not assign, transfer or otherwise dispose of any of
its rights or obligations pursuant to this Agreement without the prior written consent of Micrus.
Such consent shall not be unreasonably withheld. This Agreement shall be binding on, inure to the
benefit of, and be enforceable by the parties, their respective heirs, successors and valid
assigns.

     11.5 Notice. All notices under this Agreement shall be in writing and shall be deemed
given on the date of delivery if sent by certified or registered mail, commercial courier (return
receipt or confirmation of delivery required and costs prepaid), or by personal delivery to the
party to receive such notices or other communications called for in this Agreement at the following
addresses (or at such other address for a party as shall be specified by such party by like
notice):

If to MICRUS:

          MICRUS CORPORATION

          610 Palomar Avenue

          Sunnyvale, CA 94085

          USA

          Attention: Chief Financial Officer

If to DISTRIBUTOR:

          NEUROLOGIC (UK) LIMITED

          Albreda House, Lydgate Lane

          Sheffield S105FH United Kingdom

          Attention: Managing Director

     11.6 Limitation on Liability. In no event shall either party be liable to the other
for incidental or consequential damages, even if such party shall have been advised of the
possibility of the same.

     11.7 Force Majeure. Except for the obligation to make payments under this Agreement,
each of the parties hereto shall be excused from the performance of its obligations hereunder in
the event such performance is prevented by force majeure, and such excuse shall continue for thirty
(30) days after the termination of such force majeure. For the purposes of this Agreement, force
majeure is defined to include causes beyond the control of the parties hereto, including without
limitation, acts of God, acts, resolutions or laws of any government, war, war-like conditions,
civil commotion, destruction of production facilities or materials by fire, earthquake or storm,
labor disturbances, epidemic and failure of public utilities or common carriers.

13

 

     11.8 Publicity. Neither party shall make any press release or other similar public
disclosure or announcement concerning this Agreement, without the prior written consent of the
non-disclosing party, which consent shall
not be unreasonably withheld, except as otherwise required by law. Consent will be deemed
granted if no response is received from the non-Disclosing Party within fifteen (15) days of its
confirmed written request for approval from the Disclosing Party. Notwithstanding the foregoing, in
the event such disclosure or public announcement is required to be made on a more immediate basis
in order to comply with applicable laws, then approval will be deemed granted if no response is
received from the non-disclosing party within the timeframes required by law; provided, however,
that the Disclosing Party provides the non-disclosing party with notice of the legally required
timeframe for approval of the disclosure at the time of providing a copy of the proposed disclosure
or announcement.

     11.9 Survival of Rights. All rights to payments and the provisions of Articles I
(Definitions), VII (Confidential Information), VIII (Warranty; Indemnification), IX
(Indemnification), and XI (General Provisions), as well as Sections 2.2 (Relationship of Parties),
4.5 (Reporting), 10.8 (No Waiver), 10.9 (Effects of Termination) and 10.10 (Termination Not Sole
Remedy) shall survive the expiration or termination of this Agreement.

     11.10 Legal Expenses. The prevailing party in any legal action brought by one party
against the other and arising out of this Agreement shall be entitled, in addition to any other
rights and remedies it may have, to reimbursement for its expenses, including arbitration costs and
reasonable attorney’s fees.

     11.11 Counterparts. This Agreement may be executed in any number of counterparts, each
of which shall be an original and all of which shall constitute but one and the same document.

     11.12 Governmental Relations. In carrying out its responsibilities under this
Agreement, Distributor has not and will not pay, offer or promise to pay, or authorize the payment
directly or indirectly of any monies or anything of value to any government official or employee,
or any political party or candidates for political office for the purpose of influencing any act or
decision of such official or of the government. In the event of a breach of the representations and
warranties in the preceding sentence, this Agreement may automatically be cancelled by Micrus upon
receipt by Distributor of written notice of cancellation, and any claims for payment by Distributor
shall be surrendered. In no event shall Micrus be obligated under this Agreement to take any action
or omit to take any action that Micrus believes, in good faith, would cause it to be in violation
of any U.S. laws, including the Foreign Corrupt Practices Act, Distributor shall comply with all
laws, rules and regulations applicable to its performance of its obligations under this Agreement,
including all U.S. export control laws.

     11.13 Headings. Headings and captions are for convenience only and are not to be used
in the interpretation of this Agreement.

     11.14 Severability. If any provision of this Agreement is held to be illegal or
unenforceable, that provision shall be limited or eliminated to the minimum extent necessary so
that this Agreement shall otherwise remain in full force and effect.

     11.15 Counterparts. This Agreement may be executed in counterparts, each of which
shall be deemed an original but all of which together shall constitute one and the same
instruments. This Agreement may be executed by facsimile with original signatures promptly
following by a method set forth in Section 11.5.

14

 

     IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above
written.

BY /s/ Francois Requin

NAME: Francois Requin

TITLE: Financial Controller

 

By Mark Ellis

NAME: Mark Ellis

TITLE: Co-Director

NEUROLOGIC (UK)

MICRUS CORPORATION

 

BY /s/ E.H. Reitz

NAME: E.H. Reitz

TITLE: Executive Vice President, European Operations

NEUROLOGIC (UK) LIMITED

By J. MacKenzie

NAME: J. MacKenzie

TITLE: Director

15

 

EXHIBIT A

PURCHASE PRICE

As specified in Section 3.2.1 of the Amended and Restated Distribution Agreement, the unit pricing
of the product sold to Distributor is given in the following schedule. Each unit consists of a
micro-coil attached to a resistive heat-activated delivery device. Each unit will be packaged
sterile in an individual container and shipped to Distributor in a multi-pack shipping box. All
prices below are in Pounds Sterling (GBP).

	 	 	 	 	 
	PRODUCT	 	UNIT PRICE	 
	MICRUS PLATINUM EMBOLIC COILS
	 	 	 	 
	Spherical MicroCoil, MicruSphere 10 & 18
	 	 	[***]	 
	Helical MicroCoil, HeliPaq 10 & 18 (including HeliPaq
Stretch Resistant)
	 	 	[***]	 
	Straight MicroCoil, InterPaq
	 	 	[***]	 
	UltiPaq MicroCoil, UltiPaq
	 	 	[***]	 
	MICRUS POLYMER LOADED COILS, CERECYTE (1)
	 	 	 	 
	Cerecyte Spherical Stretch-Resistant
	 	 	[***]	 
	Cerecyte Helical Stretch-Resistant
	 	 	[***]	 
	Cerecyte Finishing Stretch-Resistant
	 	 	[***]	 
	DETACHMENT CONTROL BOX (DCB)
	 	 	[***]	 
	CONNECTING CABLES (5 per box) (CCB)
	 	 	[***]	 
	MICRUS 14 MICROCATHETER, CONCOURSE
	 	 	[***]	 

(1) Cerecyte prices are valid thru [***].

***Confidential Treatment Requested.

16

 

EXHIBIT B

MINIMUM PURCHASE REQUIREMENTS

The following schedule sets forth Distributor’s Minimum Purchase Requirements as specified in
Article VI of the Distribution Agreement. These minimums represent the cost of Products paid for by
Distributor to Micrus during each year of the Agreement.

	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	
	 	 	 	 
	 

([***]to[***])
	 	([***] to[***])
	 	([***] to[***])
	 
	 	 
	 	 
	 

[***]
	 	[***]
	 	[***]

***Confidential Treatment Requested.

17

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00079-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00079-of-00352.parquet"}]]